Weichang'an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer-Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1
Aim: Angiogenesis plays an important role in the initiation, development, and metastasis of malignant tumors. Antiangiogenic drugs combined with immune therapy are considered to have a synergistic effect on anti-tumor strategy. Weichang'an formula (WCAF) is a prescription of traditional Chinese...
Saved in:
Main Authors: | Chuan-Fang Pan (Author), Xi Zhang (Author), Jing-Wen Wang (Author), Tao Yang (Author), Linda L. D. Zhong (Author), Ke-Ping Shen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bevacizumab for glioblastoma
by: Narita Y
Published: (2015) -
Monitoring antiangiogenesis of bevacizumab in zebrafish
by: Zhang J, et al.
Published: (2018) -
Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
by: Michiko Nonaka, et al.
Published: (2018) -
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
by: Di Cao, et al.
Published: (2023) -
Bevacizumab-Induced Geographic Tongue
by: Marta Martinez-Garcia, et al.
Published: (2021)